People living with diabetes have filed a groundbreaking class-action lawsuit against the three makers of analog insulin drug products – Sanofi, Novo Nordisk and Eli Lilly – for exponentially raising consumer insulin prices in an organized scheme to drive up prices at the expense of patients who need insulin drugs to live, according to Hagens Berman.
The lawsuit states that in the last five years alone, Sanofi, Novo Nordisk and Eli Lilly have raised the sticker or “benchmark” prices on their drugs by more than 150 percent. Some plaintiffs now pay almost $900 dollars per month just to obtain the drugs they need, according to the firm.
This first-of-its-kind lawsuit details several accounts from patients resorting to extreme measures to survive rising insulin prices, including starving themselves to control their blood sugars, under-dosing their insulin, and taking expired insulin. Other class members have intentionally allowed themselves to slip into diabetic ketoacidosis – a potentially fatal blood syndrome caused by lack of insulin in the body – so that they can obtain insulin samples from hospital emergency rooms.